UKRI’s MRC awards £27.4m to University of Dundee research unit
The centre aims to discover new drug targets for diseases such as Parkinson’s and hypertension
Read More
Tag: Crohn’s disease
Study identifies new disease-inducing mechanism for inflammatory bowel disease
Combined, Crohn’s disease and ulcerative colitis affect over 500,000 people in the UK
Read More
Lab-grown ‘mini guts’ to help identify treatment for Crohn’s disease
The lifelong inflammatory bowel disease affects around one in every 350 people in the UK
Read More
Francis Crick researchers reveal pathways linking intestinal inflammation and colitis
Affecting over 500,000 people in the UK, IBD comprises Crohn’s disease and ulcerative colitis
Read More
‘Top-down’ treatment strategy dramatically improves outcomes for Crohn’s patients
Approximately 80% of patients taking Remicade from diagnosis had symptoms controlled
Read More
EMA accepts Takeda application for subcutaneous Entyvio
The company proposes to make it available in both pre-filled syringe and pen options.
Read More
Europe’s first allogeneic stem cell therapy rejected by NICE
Cost regulators for the NHS in England and Wales have not approved funding for TiGenix and Takeda’s Alofisel – the first allogeneic stem cell therapy to be approved for use across the European Union – for use in Crohn’s patients in draft guidelines.
Read More
Theravance Ireland signs deal with Janssen Biotech
Theravance Biopharma Ireland has signed a global co-development and commercialisation deal with Janssen Biotech focusing on new treatments for inflammatory intestinal conditions, including ulcerative colitis and Crohn’s disease.
Read More
Pfizer, Celltrion say data backs switch to Remicade biosimilar
Pfizer and Celltrion Healthcare have unveiled new data showing that switching patients with Crohn’s disease from Remicade to biosimilar Inflectra showed comparable efficacy, safety and tolerability over a 24-week period.
Read More
Celgene pulls plug on Crohn’s disease trials
Celgene is abandoning late-stage testing of its experimental drug mongersen for Crohn’s disease after a Data Monitoring Committee concluded that it would be futile to continue.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
